Proxy advisory firms have recommended investors vote against Strides Pharma's proposal to consolidate businesses with Steriscience and Onesource. Concerns were raised about the high valuation of Onesource and its financial challenges. The scheme aims to integrate CDMO and soft gelatine businesses for better supervision, with e-voting concluding soon.
